StreetInsider.com News Articles

Red Light Holland subsidiary signs psilocybin supply deal with Paris hospital

Mon, 08 Jun 2026 07:32:13 -0400

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) announced that its subsidiary Filament Health has signed an agreement to supply PEX010, a botanical psilocybin drug candidate, to GHU Paris Psychiatrie & Neurosciences for an academic clinical study.

The French university hospital group will use PEX010 in a randomized, double-blind, cross-over study titled "KETAPSYCHECOG: Effects of ketamine and psilocybin on behavioral and neural measures" involving healthy volunteers. The trial aims to compare behavioral and neural effects of psilocybin and ketamine.

GHU Paris, established in 2019 through the merger of three hospitals, operates 170 facilities across 94 sites in Paris and serves

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Mon, 08 Jun 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 8, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The Company is pleased to announce that Filament has signed an agreement with GHU Paris Psychiatrie & Neurosciences ("GHU Paris"), a leading French university hospital

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

Mon, 08 Jun 2026 07:30:00 -0400

The Company is pleased to announce that Filament has signed an agreement with GHU Paris Psychiatrie & Neurosciences ("GHU Paris"), a leading French university hospital

Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinica

Thu, 04 Jun 2026 07:30:00 -0400

Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity, neuroinflammatory markers, and preclinical Alzheimer's disease pathology in healthy older adults.

Toronto, Ontario--(Newsfile Corp. - June 4, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting

Red Light Holland Announces Filament Health's PEX010 Drug Candidate, the Standardized and Patented Natural Psilocybin Trusted Across 80+ Studies Globally, Selected by UCSF for Study Probing Preclinica

Thu, 04 Jun 2026 07:30:00 -0400

Filament Health will supply its standardized, patented PEX010 botanical psilocybin drug candidate, produced using proprietary extraction and stabilization methods to an independently sponsored UCSF trial examining brain activity, neuroinflammatory markers, and preclinical Alzheimer's disease pathology in healthy older adults.

Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate

Mon, 25 May 2026 08:40:00 -0400

The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.

Toronto, Ontario--(Newsfile Corp. - May 25, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company"), is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development

Red Light Holland Expands New Zealand Partnership with Allu Therapeutics to Advance Access to Filament Health's GMP-Compliant PEX010 Botanical Psilocybin Drug Candidate

Mon, 25 May 2026 08:40:00 -0400

The expanded agreement adds Filament Health, a wholly owned subsidiary of Red Light Holland, as a supplying affiliate and introduces a GMP-compliant standardized microdose format of PEX010 supported by long-term stability and safety data.

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechani

Thu, 14 May 2026 08:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 14, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. Red Light is pleased to confirm additional shipments of Filament Health's PEX010 supporting:

Bruyère Health Research Institute ("Bruyère") – Ongoing shipments in support of the Microdose Open Label Extension

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Advances PEX010 Clinical Footprint with New Canadian Academic Studies in Palliative Care, Bipolar II Depression, and Healthy Adult Mechani

Thu, 14 May 2026 08:30:00 -0400

Bruyère Health Research Institute ("Bruyère") – Ongoing shipments in support of the Microdose Open Label Extension

Form D Red Light Holland Corp.

Wed, 13 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26486772.html

Form D Red Light Holland Corp.

Wed, 13 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26486772.html

Form D Red Light Holland Corp.

Wed, 13 May 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260513/26486772.html

Red Light Holland shareholders approve name change, CFO resigns

Wed, 13 May 2026 09:14:48 -0400

Red Light Holland Corp. (CSE: TRIP) announced shareholders approved a corporate name change at the company's annual meeting held May 11, 2026, in Toronto. The special resolution received what the company described as overwhelming shareholder support.

The company stated it continues to evaluate and finalize the new corporate name and will announce the effective date once regulatory authorities and the Canadian Securities Exchange complete their processes.

Shareholders also approved the re-appointment of the company's auditor, a proposed share consolidation, and elected all nominated directors. The elected directors are Todd Shapiro, Brad J. Lamb, Michael Galloro, Binyomin Posen, and Ben Lightburn.

Red Light Holland

Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders

Wed, 13 May 2026 09:12:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light Holland" or the "Company") is pleased to announce that shareholders overwhelmingly approved the Company's proposed corporate name change at the Company's annual general and special meeting of shareholders ("Shareholders") held on Monday, May 11, 2026 at the Company's office in Toronto (the "Meeting").

The special resolution approving the Company's proposed name change received overwhelming shareholder support. The Company is continuing to evaluate and finalize its new corporate name and will announce the effective date of the name change once finalized with

Red Light Holland Announces Shareholder Approval of Name Change and Announces Voting Results from 2026 Annual General and Special Meeting of Shareholders

Wed, 13 May 2026 09:12:00 -0400

Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intell

Fri, 08 May 2026 07:30:00 -0400

Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events
Filament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authorization
Filament's lead botanical psilocybin drug candidate, PEX010, has received Phase 2 clinical trial authorization in stimulant use disorder from both the U.S. Food and Drug Administration and Health Canada, providing a clear regulatory path

Red Light Holland Highlights Publication of Randomized Clinical Trial Showing a Single Dose of Psilocybin Reduced Cocaine Use, with Filament Health Holding the Exclusive License to the Data and Intell

Fri, 08 May 2026 07:30:00 -0400

Peer-reviewed results published yesterday (May 7, 2026) in JAMA Network Open demonstrate that a single dose of psilocybin meaningfully reduced cocaine use in adults with cocaine use disorder over six months, with no serious adverse events
Filament Health Corp., a wholly-owned subsidiary of Red Light Holland, holds the exclusive worldwide license to the trial data and certain associated intellectual property, with the goal of supporting future regulatory authorization
Filament's lead botanical psilocybin drug candidate, PEX010, has received Phase 2 clinical trial authorization in stimulant use disorder from both the U.S. Food and Drug Administration and Health Canada, providing a clear regulatory path

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions

Thu, 07 May 2026 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - May 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) (FSE: 4YX) ("Red Light" or the "Company") is an Ontario-based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical-grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. Red Light is pleased to confirm additional shipments of Filament Health's PEX010 supporting:

University of Calgary ("UCalgary") - Second shipments in support of ongoing clinical studies in Alcohol Use Disorder

Red Light Holland's Wholly Owned Subsidiary, Filament Health, Expands Distribution of PEX010 Across Canadian and U.S. Research Institutions

Thu, 07 May 2026 07:30:00 -0400

University of Calgary ("UCalgary") - Second shipments in support of ongoing clinical studies in Alcohol Use Disorder

Red Light Holland Announces Intention to Rebrand

Mon, 04 May 2026 08:30:00 -0400

New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments
Name change resolution to be voted on by shareholders at the upcoming Annual General and Special Meeting ("AGSM") on May 11, 2026
Company urges all shareholders to vote IN FAVOUR of the name change resolution to support the rebranding exercise
Rebranding reflects the combined focus on clinical research, GMP manufacturing, FDA-aligned drug development, and the advancement of patented botanical psychedelic drug candidates including PEX010

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF)

Red Light Holland Announces Intention to Rebrand

Mon, 04 May 2026 08:30:00 -0400

New name and branding to be announced in the coming weeks, better aligned with the Company's scientific mandate and all business segments
Name change resolution to be voted on by shareholders at the upcoming Annual General and Special Meeting ("AGSM") on May 11, 2026
Company urges all shareholders to vote IN FAVOUR of the name change resolution to support the rebranding exercise
Rebranding reflects the combined focus on clinical research, GMP manufacturing, FDA-aligned drug development, and the advancement of patented botanical psychedelic drug candidates including PEX010

Toronto, Ontario--(Newsfile Corp. - May 4, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF)

Red Light Holland completes acquisition of Filament Health

Thu, 30 Apr 2026 07:37:13 -0400

Red Light Holland Corp. (CSE: TRIP) completed its acquisition of Filament Health Corp. (OTC: FLHLF) on April 29, 2026, through a statutory plan of arrangement under British Columbia's Business Corporations Act, according to a company statement.

Under the transaction terms, Red Light acquired all 270,728,040 outstanding Filament shares at an exchange ratio of 0.36634769 Red Light shares per Filament share. The company issued 99,180,497 consideration shares and an additional 70,836,683 shares for debt settlements. Former Filament shareholders now hold approximately 30% of Red Light's 595,727,901 total outstanding shares.

The acquisition brings together Red Light's distribution network with Filament's pharmaceutical development capabilities and

Red Light Holland completes acquisition of Filament Health

Thu, 30 Apr 2026 07:37:13 -0400

The acquisition brings together Red Light's distribution network with Filament's pharmaceutical development capabilities and

Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution

Thu, 30 Apr 2026 07:30:00 -0400

Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution
Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies
Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities
Positions the Company at the forefront of the rapidly emerging regulated psychedelic medicine industry
Advances clinical pipeline, including PEX010, while expanding access to natural psilocybin products globally
Establishes a regulated pipeline of psychedelic compounds, including ibogaine, MDMA, and psilocybin, supporting next-generation drug discovery and IND-enabled clinical development within compliant frameworks

Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX)

Red Light Holland Completes Acquisition of Filament Health, Creating a Global Leader in Psychedelic Drug Development, Commercialization and Distribution

Thu, 30 Apr 2026 07:30:00 -0400

Establishes a vertically integrated platform spanning pharmaceutical-grade botanical drug development and global consumer distribution
Adds Filament's extensive intellectual property portfolio, including 70+ patents and proprietary extraction technologies
Leverages Health Canada Dealer's License and FDA-aligned clinical development pathways, including IND-enabled activities
Positions the Company at the forefront of the rapidly emerging regulated psychedelic medicine industry
Advances clinical pipeline, including PEX010, while expanding access to natural psilocybin products globally
Establishes a regulated pipeline of psychedelic compounds, including ibogaine, MDMA, and psilocybin, supporting next-generation drug discovery and IND-enabled clinical development within compliant frameworks

Toronto, Ontario--(Newsfile Corp. - April 30, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX)